Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Cue Biopharma’s off-the-shelf biologics are designed to modulate the activity of a patient’s immune system utilizing a modular, rationally engineered therapeutic framework that mimics nature’s own signals, or “cues,” in selectively stimulating or inhibiting disease-relevant T cells for cancers and infections or autoimmune diseases, respectively. In this way, Cue Biopharma’s biologics avoid the systemic and indiscriminate immune activation (in cancer or infectious disease) or broad immunosuppression (in autoimmune diseases) of available immune-modulating drugs that can lead to deleterious effect, adverse events, dose-limiting toxicities, treatment discontinuation, and inadequate efficacy.
Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
Jan 20 | 2022
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
Jan 05 | 2022